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Table. Clinical Outcomes at 24 Months According to DAPT Duration and DAPT
Status at The Time of Event
Events
a
DAPT
Cessation at
1-6 Months
N¼41
b
DAPT
Cessation at
6-12 Months
N¼538
c
DAPT
Cessation at
12-24 Months
N¼648
d
No DAPT
Cessation
N¼673 p-value
a vs. d
b vs.
d
c vs.
d
All
Groups
ID-TVF 2.4 (1) 7.43 (40) 4.63 (30) 9.21 (62) 0.25 0.27 0.001 0.007
DAPT-on 0 (0) 87.5 (35) 86.7 (26) 100.0 (62)
DAPT-off 100.0 (1) 12.5 (5) 13.3 (4) 0 (0)
Def/Pro
ST
0 (0) 0.74 (4) 0.77 (5) 0.6 (4) 1.00 0.74 0.75 0.91
DAPT-on - 75.0 (3) 100.0 (5) 100.0 (4)
DAPT-off - 25.0 (1) 0 (0) 0 (0)
Bleeding
( type
II)
24.39 (10) 4.28 (23) 2.93 (19) 1.49 (10) <0.0001 0.003 0.07 <0.0001
DAPT-on 70.0 (7) 78.3 (18) 94.7 (18) 100.0 (0)
DAPT-off 30.0 (3) 21.7 (5) 5.3 (1) 0 (0)
Data are presented as % (n)
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Background: A sizeable proportion of patients treated with PCI are unable to take
dual antiplatelet therapy (DAPT) for the guideline-recommended period of 6-12
months. Optimal treatment of patients at high bleeding risk thus remains uncertain.
The BioFreedom drug-coated stent (DCS) (Biosensors Europe SA, Morges,
Switzerland) is polymer- and carrier-free, releases Biolimus A9 into the vessel wall
over a period of 28 days, and then technically becomes a BMS.
Methods: 2465 patients at high bleeding risk from 68 centers in Europe, Asia, and
Canada were enrolled from Dec 2012 to May 2014 in a double-blinded randomized
1:1 comparison of Gazelle BMS (Biosensors Europe SA, Morges, Switzerland) vs.
BioFreedom DCS with a 1 month course of DAPT only, in both arms. The 2 primary
endpoints at 1 year are a composite of cardiovascular death, MI and stent thrombosis
for safety and the rate of ci-TLR for efﬁcacy. The DSMB is monitoring all safety data
at 4 months.
Results: In the overall trial population, the most frequently used inclusion criteria
were: advanced age (64%), need for long term oral anticoagulation (36%), anemia,
recent bleeding or transfusion (21%), renal insufﬁciency (19%), planned surgery
(15%) and concomitant cancer (9%). When compared to those included in “all-comer”
trials, patients were markedly older (769.4 years), and had more co-morbidities
(diabetes 33%, atrial ﬁbrillation 34%, peripheral vascular disease 16%, heart
failure 13%, prior stroke 10%, COPD 11%). 1.7 stents/patients were implanted for a
total stent length of 32 mm/patient. Technical procedure success was high at
96%. 66% of patients were discharged on DAPT alone, 30% on DAPT + oral anti-
coagulation, and 2% on a single antiplatelet agent + oral anticoagulation. Current data
are preliminary; Data from all recruited patients will be available at time of
presentation.
Conclusions: The trial is a ﬁrst in 3 ways: it focuses on a never previously studied
high bleeding risk population, characterized by advanced age and more comorbid
conditions. It is the ﬁrst evaluation of a DCS with clinical endpoints and it comprises
the shortest ever DAPT course with an active stent to be evaluated for both safety and
efﬁcacy.
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Background: Drug eluting stents (DES) have been associated to an increased risk of
late stent thrombosis. The recommendation for dual antiplatelet therapy (DAPT) is for
12 months, nevertheless this strategy is expensive and associated to a variable
bleeding risk. Recent limited in size trials have suggested that 6 months DAPT could
be safe but large real practice registries are still lacking.
Methods:We enrolled prospectively consecutive patients treated with new generation
DES from 18 Spanish centers that were discharged with a 6 month DAPT prescription.
Patients to include should meet at least one of the following criteria: silent ischemia,
stable angina, low risk acute coronary syndrome (ACS) or any ACS with no-low
bleeding risk. The adherence to the 6 months DAPT period was veriﬁed at follow up.
In order to compare outcomes with a 12 months DAPT strategy we performed a
propensity score matched analysis with the large cohort of patients from theB144 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstramulticenter prospective ESTROFA-2 database (4,354 patients treated with second
generation DES and at least 12 month DAPT).
Results: A total of 2,572 matched patients were included (1,286 in each group) with
well balanced baseline clinical, angiographic and procedural characteristics. Admis-
sion diagnose was ACS in 40-41% of the patients in both groups. The incidence of
deﬁnite stent thrombosis at 12 months follow up was 0.4% in 6 month-DAPT group
and 0.6% in 12 months-DAPT group (p¼0.4) and the incidence of deﬁnite/probable
thrombosis was 0.7% in 6 month-DAPT group and 1.5% in 12 months-DAPT group
(p¼0.09). The incidence of deﬁnite/probable thrombosis between 6 and 12 months
after DES implantation was 0.2% in the 6 months-DAPT group and 0.3% in the 12
months-DAPT group (p¼0.7).
Conclusions: A DAPT period of 6 months compared to 12 months after implanta-
tion of new generation DES resulted safe in the selected patients of this multicenter
study.
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Background: Appropriate duration of dual antiplatelet therapy (DAPT) after drug-
eluting stent implantation is still controversial. We sought to assess the associations
between DAPT cessation, ischemic events and bleeding risks following PCI in pa-
tients with complex lesions treated with the cobalt-chromium (CoCr) everolimus-
eluting stent (EES).
Methods: 1900 patients with small vessel (reference diameter < 2.75 mm), long
lesion (length >25 mm), or multivessel (>2 target vessels) disease who underwent
PCI with EES (Xience V, Abbott Vascular, Santa Clara, CA, USA) in the prospective
SEEDS study were categorized into 4 groups according to DAPT duration (1-6
months, 6-12 months, 12-24 months after PCI and no DAPT cessation). All events
were classiﬁed into “on DAPT” or “off DAPT” group according to the DAPT status at
the time of event occurred. Clinical follow-up data at 2 years were analyzed for all.
The major outcomes were ischemia-driven target vessel failure (ID-TVF), a composite
of cardiac death, target vessel myocardial infarction, or ischemia-driven target vessel
revascularization, deﬁnite/probable stent thrombosis (ST), and BARC bleeding II-V at
2 years.
Results: DAPT cessation after 12 months following the index PCI decreases the risks
of ID-TVF, but not ST compared to no DAPT cessation group. Among the 13 deﬁnite/
probable ST events, 12 (92.9%) of them occurred on DAPT and 1 occurred off DAPT.
On the other hand, use of DAPT was a strongly independent predictor of BARC
bleeding (HR [95%CI]: 9.82 [4.64,20.80], p< 0.0001) at 2 years. However, adverse
events occurred on DAPT was increased overtime (table).Conclusions: The present study demonstrated that DAPT cessation was not associated
with an increase in adverse ischemic events and might suggest that shorter DAPT
duration is reasonable to decrease bleeding complications in Chinese patients
receiving a CoCr EES. (ClinicalTrials.gov identiﬁer: NCT 01157455)cts/Pharmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors
